Tag: medical marijuana

Medical Marijuana ‘Significantly’ Decreases Use Of Opioids By Chronic Pain Patients, New Study Finds

A new study is offering more evidence that marijuana can serve as an effective substitute for opioids in pain management treatment.

Researchers in Australia at Murdoch University and the Perth Pain Management Centre set out to investigate how the integration of cannabinoids into treatment for people with chronic non-cancer pain would impact opioid use.

The study, published in the journal Pain Management on Monday, determined that “co-prescription of cannabinoids may enable patients to reduce their opioid consumption prescribed for chronic benign pain.”

To assess the relationship between cannabis and opioids in treatment, researchers followed two cohorts of patients over the course of a year: One group of 102 patients at a pain clinic who were already taking opioids and were co-prescribed cannabis and another group of 53 patients at a different clinic who were only receiving opioids, without marijuana.

At the baseline, the median patient was taking about 40 mg of opioids per day. After a year, the group that received a median dose of medical cannabis containing 15 mg delta-9 THC and 15 mg of CBD “significantly” decreased their opioid dose to 2.7 mg per day. The opioid-only cohort after one year was taking a median 42.3 mg per day.

“The introduction of cannabinoids can produce useful reductions in opioid consumption in real-world settings, with additional benefits for disability and insomnia,” the study authors said. “However, this treatment is tolerated by only a subgroup of patients.”

Among the cohort that incorporated cannabis into their treatment regiment, “opioid consumption decreased significantly after both 6 and 12 months.”

“Physical activity and sleep also improved. These findings indicate that medicinal cannabis can help patients to reduce their opioid consumption and improve their physical activity and sleep,” the study concluded.

The findings are also consistent with a growing body of scientific literature exploring the association between cannabis and opioid use.

For example, a study published earlier this year in the journal Drug and Alcohol Review found that, among drug users who experience chronic pain, daily cannabis use was linked to a higher likelihood of quitting the use of opioids—especially among men.

A study published late last year also found that legalizing medical cannabis appeared to significantly reduce monetary payments from opioid manufacturers to doctors who specialize in pain, with authors finding “evidence that this decrease is due to medical marijuana becoming available as a substitute” for prescription painkillers.

Keep reading

Medical Marijuana Reduces Anxiety And Depression, New Federally Funded Study Shows

Medical marijuana was associated with “significant decreases in self-reported anxiety and depression” compared to before patients began treatment with cannabis, according to a new study funded in part by the National Institute on Drug Abuse (NIDA).

The observational study, published this month in the Journal of Affective Disorders, looked at 33 adults in Maryland with “clinically significant” anxiety and/or depression over a six-month period, evaluating them at baseline, and then again after one, three and six months from when patients began using medical cannabis.

“Significant decreases from baseline in anxiety and depression were observed, with mean scores dropping below clinically significant levels within three months of initiation,” the study says. Participants also reported sustained reductions in anxiety and/or depression symptoms over the six-month study period.

Most patients chose THC-dominant cannabis products. In addition to self-reported benefits to mental health, they also reported a decline in their perceived driving ability and an increase in feeling high.

“Acute effects were dose-dependent,” authors wrote: “10–15 mg of oral THC and at least 3 puffs of vaporized cannabis yielded the most robust reductions in anxiety and depression.”

Among participants, three-quarters said they had previously used marijuana. Just over a third (37 percent) said they’d used cannabis within the past year.

At the time of the study, medical marijuana was legal in Maryland but the substance remained illegal for nonmedical use.

The six-person team behind the new study represents the Johns Hopkins University School of Medicine, the Johns Hopkins School of Public Health and the university’s Sidney Kimmel Comprehensive Cancer Center, as well as the Centre for Alcohol Policy Research in Melbourne, Australia.

A conflict of interest section of the report notes that some members have received funding or currently work for companies involved in medical marijuana.

In addition to NIDA funding, the project also received support a pilot grant from the Lambert Center for the Study of Medicinal Cannabis and Hemp at Thomas Jefferson University.

Authors said that while the findings of the new study were promising, “controlled clinical trials are needed to further investigate the efficacy and safety of medicinal cannabis for acute anxiety and depression symptom management.”

Keep reading

Hawaii Governor Signs Medical Marijuana Expansion Bill, After Calling One Of Its Provisions ‘A Grave Violation Of Privacy,’

On the heels of signaling a possible veto of a bill meant to expand access to medical marijuana in Hawaii, Gov. Josh Green (D) instead signed the measure into law over the weekend, regardless of a provision he recently described as “a grave violation of privacy.”

HB 302 will make two main reforms around patient access. First, it allows a patient’s primary treating medical provider to recommend marijuana for any malady they see fit, regardless of whether it’s a specified qualifying condition in Hawaii. It also allows patients to receive medical cannabis recommendations through telehealth visits rather than having to establish an in-person relationship with a provider.

Before lawmakers sent the bill to Green, a conference committee revised the plan, inserting a provision to allow the state Department of Health to access medical marijuana patient records held by doctors for any reason whatsoever.

The revised bill authorizes the Department of Health to “inspect a qualifying patient’s medical records held by the physician, advanced practice registered nurse, or hospice provider who issued a written certification for the qualifying patient.” Providers who don’t comply with a department request for a patient’s records could see their ability to issue medical cannabis revoked.

Advocates initially supported HB 302 as a means to expand access to patients with conditions beyond those specified under state law. But many withdrew support following the conference committee’s changes.

An additional provision establishes a new Class C felony for unlicensed operation of a dispensary, adding another major charge on top of the state’s existing laws against illegal distribution of marijuana.

In early June, Green himself put the cannabis measure on a list of bills he intended to veto—an indication, though not a commitment, that he was leaning towards rejecting it.

“Although this bill’s authorization of medical cannabis certifications via telehealth expands access to medical cannabis,” his office wrote at the time, “provisions authorizing the inspection of patients’ medical records without warrant constitute a grave violation of privacy.”

Keep reading

DeSantis Signs Bill To Strip Florida Medical Marijuana Cards From People With Drug Convictions

Some medical marijuana patients and caregivers in Florida could see their state cannabis registrations revoked under a bill signed into law by Gov. Ron DeSantis (R) this week.

DeSantis on Monday signed SB 2514, a broad budget bill that touches on cancer, dentistry and other health-related matters. But it also contains a provision that directs the state Department of Health (DOH) to cancel registrations of medical marijuana patients and caregivers if they’re convicted of—or plead guilty or no contest to—criminal drug charges.

The measure says a patient or caregiver would have their registration immediately suspended upon being charged with a state drug crime, and the suspension would remain in place until the criminal case reaches a final disposition.

DOH officials would have authority to reinstate the registration, revoke it entirely or extend the suspension if needed.

Authorities would be required to revoke a person’s registration if the patient or caregiver “was convicted of, or pled guilty or nolo contendre to, regardless of adjudication, a violation [of state drug law] if such violation was for trafficking in, the sale, manufacture, or delivery of, or possession with intent to sell, manufacture, or deliver a controlled substance.”

The enacted version of the legislation focuses specifically on production and distribution. It does not contain an earlier restriction from prior versions that would have also revoked registrations for people who merely purchased illegal drugs, including more than 10 grams of marijuana for their own use.

It also clarifies that patients and caregivers would have a process to request their registrations be reinstated. That would involve submitting a new application “accompanied by a notarized attestation by the applicant that he or she has completed all the terms of incarceration, probation, community control, or supervision related to the offense.”

It’s not clear from the plain language of the revised bill whether it would impact only future criminal cases involving medical marijuana patients and caregivers or whether DOH would need to review the records of existing program registrants and revoke registrations of an untold number of Floridians with past drug convictions.

Keep reading

White House Announces Withdrawal Of Trump’s Drug Czar Nominee Who Embraced Medical Marijuana

The White House has notified Congress that President Donald Trump’s nominee to lead the Office of National Drug Control Policy (ONDCP)—who has publicly backed medical marijuana access—is being withdrawn.

About three months after Trump picked Sara Carter to become the next White House drug czar, the administration told lawmakers on Thursday that she’s no longer up for consideration for the position.

It’s currently unclear whether Carter withdrew from consideration herself or if it was a decision made by the president. Marijuana Moment reached out to the White House for comment, but a representative did not respond by the time of publication.

The notice published in the Congressional Record about the withdrawal of the nomination reads:

“WITHDRAWAL

Executive Message transmitted by the President to the Senate on June 26, 2025 withdrawing from further Senate consideration the following nomination:

SARA CARTER, OF TEXAS, TO BE DIRECTOR OF NATIONAL DRUG CONTROL POLICY, VICE RAHUL GUPTA, RESIGNED, WHICH WAS SENT TO THE SENATE ON MAY 6, 2025.”

There was some enthusiasm about Carter’s nomination among cannabis reform advocates, as she’s previously called medical marijuana a “fantastic” treatment option for seriously ill patients and said she doesn’t have a “problem” with legalization, even if she might not personally agree with the policy.

Given the role of ONDCP director in setting and carrying out the administrative agenda on drug policy issues, the fact that Carter went on the record enthusiastically endorsing medical cannabis represented a welcome development for advocates amid Senate confirmations of other officials with a mixed bag of marijuana records.

Under longstanding federal statute, the drug czar is prohibited from endorsing the legalization of Schedule I drugs in the Controlled Substances Act (CSA), including marijuana. However, Democratic congressional lawmakers in April filed a bill that would remove that restriction.

Keep reading

Nebraska Medical Marijuana Regulators Approve Emergency Rules Banning Flower Access For Patients

The Nebraska Medical Cannabis Commission on Thursday approved emergency regulations to begin accepting medical cannabis applications as soon as Gov. Jim Pillen (R) gives his final green light.

State law requires him to do so by Tuesday.

The emergency regulations, unveiled for the first time minutes before the 10 a.m. meeting, largely mirror a legislative proposal that lawmakers stalled on last month. The regulations would take effect for up to 90 days, pending Pillen’s approval. The two medical cannabis-related laws that voters approved mandate that applications must start being accepted no later than July 1.

Commissioner Lorelle Mueting of Gretna, an addiction prevention specialist through Heartland Family Service, affirmed that commissioners want public feedback on the emergency regulations through July 15, to inform future, formal regulations.

Public comments may be submitted to lcc.frontdesk@nebraska.gov, the repository for the Nebraska Liquor Control Commission, which will forward the messages onto the state’s new Medical Cannabis Commission.

“The input that the public provides on these emergency regulations will help us immediately begin drafting the regular regulations,” Mueting said Thursday.

Keep reading

Nebraska Medical Cannabis Commission Proposal Will ‘Destroy Patient Access,’ Advocates Say

It’s unclear what requirements the state commission to regulate medical cannabis in Nebraska might enact to license such operations by this fall, ahead of a deadline next week for detailing the criteria for applications.

The Nebraska Medical Cannabis Commission has until July 1 to write licensing criteria under state law. But as commissioners gear up for their next meeting Thursday, the first with all five commissioners, they have indicated they will consider adopting draft or emergency criteria to accept or deny licensing applications after July 1.

Licensing must begin by October 1, the same time any other requirements for medical cannabis must be enacted, according to a pair of laws that voters overwhelmingly approved in a pair of November ballot measures.

However, with just hours until the next commission meeting, there is no specific indication of what criteria the board will consider.

Also on the agenda is a legal “memorandum of agreement” to help with future rulemaking involving the Nebraska Department of Health and Human Services (DHHS) and Gov. Jim Pillen’s (R) Policy Research Office, the policy lobbying arm of the state’s chief executive.

No draft rules or regulations, including licensing criteria, have yet been made public.

Crista Eggers, executive director of Nebraskans for Medical Marijuana, which has led medical cannabis ballot measures since 2020, said she’s faced a lack of transparency and been unable to reach the commission or have questions answered in recent weeks, leaving many advocates “extremely frustrated.”

“I didn’t know we could be more frustrated than what we have been previously, but there just seems to be a new layer added every single day,” Eggers said Tuesday.

Keep reading

U.S. House Approves Amendment Allowing VA Doctors to Recommend Medical Cannabis to Veterans

The U.S. House of Representatives has approved an amendment that would allow Department of Veterans Affairs (VA) physicians to recommend medical marijuana to veterans in states where it’s legal.

The measure, introduced by Representatives Brian Mast (R-FL) and Dave Joyce (R-OH), was adopted as part of the Military Construction, Veterans Affairs, and Related Agencies Appropriations Act (H.R. 3944). The overall bill is expected to receive a final vote on the House floor soon.

The amendment would prohibit the VA from using federal funds to enforce a longstanding policy that prevents VA doctors from assisting patients with enrolling in state-approved medical marijuana programs. Under current rules, VA physicians are barred from discussing or filling out the necessary paperwork for veterans to access legal marijuana, even in the 39 states that allow its use for medical purposes.

The amendment states:

“None of the funds appropriated or otherwise made available to the Department of Veterans Affairs in this Act may be used to enforce Veterans Health Directive 1315 as it relates to:

(1) the policy stating that ‘VHA providers are prohibited from completing forms or registering Veterans for participation in a State-approved marijuana program’;

(2) the directive for the ‘Deputy Under Secretary for Health for Operations and Management’ to ensure that ‘medical facility Directors are aware that it is VHA policy for providers to assess Veteran use of marijuana but providers are prohibited from recommending, making referrals to or completing paperwork for Veteran participation in State marijuana programs’; and

(3) the directive for the ‘VA Medical Facility Director’ to ensure that ‘VA facility staff are aware of the following’ ‘[t]he prohibition recommending, making referrals to or completing forms and registering Veterans for participation in State-approved marijuana programs.

Two bills have been filed this year in the House that would take a similar approach in easing access to medical cannabis for veterans, the Veterans Cannabis Use for Safe Healing Act and the Veterans Equal Access Act, filed by Rep. Gregory Steube (R-FL) and Brian Mast (R-FL).

Keep reading

Missouri Marijuana Officials Are Reviewing Rules On Purchase Limits For Medical Patients

Cannabis advocacy organizations are sounding the alarm about guidance from state regulators limiting how much medical marijuana patients can purchase from licensed dispensaries.

By law, dispensaries are required to track how much medical marijuana patients buy so they don’t exceed their limit.

According to a FAQ that was added earlier this year to the website of the Missouri Department of Health and Senior Services, the state’s cannabis regulatory agency, if patients reach their limit they are not legally allowed to buy marijuana like as a recreational consumer.

“…patient ID card holders are not allowed to purchase as a consumer in a licensed dispensary,” the website states. “These regulations help ensure patients and consumers stay within their allowed possession limits.”

In general, medical patients are limited to a 6-ounce allotment of dried, unprocessed marijuana every 30 days. Recreational consumers are allowed to purchase up to 3 ounces every day—but can’t possess more than 3 ounces.

The state is prohibited by law from tracking the purchases of people who don’t have patient ID cards without their permission.

Andrew Mullins, executive director of the Missouri Marijuana Trade Association, sent a letter to leaders of the Division of Cannabis Regulation in April claiming the policy is unconstitutional.

“We believe that DCR’s interpretation that a Missourian must either be an adult-use consumer or a medical patient is neither good public policy nor a constitutionally sound interpretation,” he wrote.

Keep reading

Texas Governor Signs Bill To Significantly Expand State’s Medical Marijuana Program

The governor of Texas has approved a bill to to significantly expand the state’s medical marijuana program.

As advocates and stakeholders await the fate of a separate measure banning consumable hemp products, Gov. Greg Abbott (R) on Saturday signed into law the medical cannabis legislation from Rep. Ken King (R).

The new law will expand the state’s list of medical cannabis qualifying conditions to include chronic pain, traumatic brain injury (TBI), Crohn’s disease and other inflammatory bowel diseases, while also allowing end-of-life patients in palliative or hospice care to use marijuana.

The measure additionally allows patients to access a wider range of cannabis product types—including patches, lotions, suppositories, approved inhalers, nebulizers and vaping devices.

And, it mandates that the Department of Public Safety (DPS) increase the number of medical cannabis business licenses from the current three to 15. It further allows dispensaries to open satellite locations.

Before moving to the governor’s desk, House lawmakers had rejected Senate changes to the bill, which largely scaled back the scope of the proposed expansion to the medical marijuana program.

The version passed by the House last month would have extended the currently limited list of medical cannabis qualifying conditions to include chronic pain, glaucoma, TBI, spinal neuropathy, Crohn’s disease or other inflammatory bowel disease and degenerative disc disease.

It would also have allowed military veterans to become registered cannabis patients for any medical condition—and authorized the Texas Department of State Health Services (DSHS) to further expand the list of qualifying conditions.

But those provisions were removed in the Senate State Affairs Committee before the bill reached the floor of that chamber.

Rep. Tom Oliverson (R) suggested there was an agreement around adding chronic pain with Lt. Gov. Dan Patrick (R), the presiding officer of the Senate. While Patrick disputed the characterization of their conversation, the lieutenant governor and lawmakers ultimately reached a deal to reinsert the condition into the bill with an amendment that passed on the Senate floor, among others.

Whereas the Senate version had said that chronic pain patients could only access medical cannabis if they had first tried opioids for 90 days, the final version crafted by the conference committee does not contain such a stipulation. And, under the agreement, TBI is being added back in as a new qualifying condition as well.

Keep reading